What You Should Know:
Quest Diagnostics has reached an agreement to acquire Haystack Oncology an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisionsUnder the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Komodo Health Launches MapEnhance; Changing the Paradigm for Health Data Utilization
What You Should Know:
Komodo Health unveils MapEnhance, a network of speciality data partners that seamlessly connects new datasets — including genomic, lab, cost and clinical insights — to Komodo's Healthcare Map, to drive faster and timelier insights across healthcare and Life Sciences.With MapEnhance, Komodo is bringing the industry a more seamless way to leverage clinical intelligence and customize data inputs from a variety of real-world data sources,
Read More
Drug Discovery Outsourcing Market Expected to Reach $7.5B by 2033
What You Should Know:
The drug discovery outsourcing market is expected to reach $3.75B in 2023 and is expected to grow at a steady CAGR of 7.2% and is expected to reach $7.52B by 2033, according to a new report by Future Market Insights.The research report on the drug discovery outsourcing market states that the pharmaceutical industry is expanding thoroughly with new extensions and high-end research programs.
AI Drug Discovery Outsourcing for Cost-Savings
The
Read More
Biostage Raises $6M to Advance Clinical Trials
What You Should Know:
Biostage, Inc., a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer and FDA approval to commence a clinical trial of the Biostage Esophageal Implant raises $6M from new and existing investors in a private placement of its shares of common stock.The funds will be used to accelerate the clinical development of Biostage’s lead product candidate, the Biostage Esophageal Implant, or BEI. The FDA has approved a
Read More
PsychoGenics Launches AI Platform to Revolutionize Drug Discovery
What You Should Know:
- PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform.
The platform supports phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
How eCube Works
eCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained
Read More
Exec Hires: Clinical Trials Marketplace SubjectWell Appoints New CEO
What You Should Know:
- SubjectWell, the largest engagement platform for matching patients with chronic health conditions to new care options, announced that clinical industry veteran Fred Martin has joined SubjectWell as CEO.
- Fred will joins SubjectWell during a time of growth following the company’s Series B funding in November 2022, with the goal of accelerating technical solutions and building investor relations.
Fred Martin Bio
Fred brings more than 25 years of experience in
Read More
Dot Compliance Launches First AI Based ChatGPT Powered eQMS for Life Sciences
What You Should Know:
Dot Compliance, a leading provider of eQMS compliance solutions for the life sciences sector, has introduced an industry-first, ready-to-use AI-Based electronic Quality Management System for life sciences, powered by an embedded generative and predictive artificial intelligence.The system deploys ChatGPT combined with proprietary algorithms to optimize quality processes, automate tasks and help professionals working in quality assurance to focus on what really matters
Read More
Can Technology Live Up to Its Promise for Clinical Trials?
By creating efficiencies with technology, CROs have an opportunity to build clinical trials of the future.
For many years, artificial intelligence (AI), machine learning (ML) and natural language processing (NLP) had a reputation in the biopharmaceutical industry as flashy buzzwords, with little concrete evidence to back up their promise. Over time, this lack of understanding has created drawn-out anticipation, leaving many skeptical about the true value of these tools.
As the
Read More
Inato Raises $20M to Make Clinical Trials More Inclusive
What You Should Know:
- Inato, a technology platform that connects pharma companies (trial sponsors) with community-based trial sites raises $20M in new funding (A2) led by Cathay Innovation with participation from existing investor Obvious Ventures and new investors La Maison and Top Harvest Capital. Inato works with many of the top 30 pharmaceutical companies worldwide to make clinical trials more inclusive.
- The new funding will fuel Inato’s continued product innovation, international
Read More
Exploring The Value of Metaverse Use Cases in Life Sciences
What once seemed like science fiction, interacting with people across the world has become the new normal. While we have become increasingly accustomed to video calls and instant communication in recent years, forays into virtual worlds and extended realities are still relatively novel.
In a post-Covid world, it seems strange to think that video conferences and calls were not the norm only three years ago. But the value created by virtual interactions during the last several years has
Read More
